EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clostridium Scindens Protects Against Vancomycin‐Induced Cholestasis and Liver Fibrosis by Activating Intestinal FXR‐FGF15/19 Signaling

Jintao Xiao iD, Yanliang Hou, Xingyang Luo, Yuhao Zhu, Wenhu Li, Bingbing Li, LinXiang Zhou, Xia Chen, Ying Guo, Xiaomei Zhang, Haiyue He, Xiaowei Liu iD

Advanced Science · 2025-02 · 12 (5)

DOI: 10.1002/advs.202406445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 16.12.2024. Verfasst von Jintao Xiao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. Hauptthemen laut MEDLINE: Vancomycin, Fibroblast Growth Factors, Liver Cirrhosis, Cholestasis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary sclerosing cholangitis (PSC) is characterized by abnormal bile acid metabolites and altered gut microbiota, with no effective treatments available. Vancomycin, a glycopeptide antibiotic, has emerged as a promising candidate. However, the mechanism by which vancomycin impacts the progression of PSC remains unknown. Mice treated with vancomycin exhibit increased hepatic collagen deposition and injury, due to the inhibition of intestinal FXR‐FGF15/19 axis and the elevation of bile acid levels. These effects are associated with the reduction in Clostridia XIVa , especially Clostridium scindens ( C. scindens ). Gavage of C. scindens alleviates vancomycin‐induced bile acid accumulation and liver fibrosis via activating intestinal FXR‐FGF15/19 signaling. Similar effects are observed in mice treated with engineered Escherichia coli Nissle 1917 that are capable of expressing bile acid 7α‐dehydratas (BaiE) from C. scindens (EcN‐BaiE). Activating intestinal FXR‐FGF15/19 signaling by fexaramine (Fex) or recombinant protein FGF19 reverse vancomycin‐induced liver injury and fibrosis. These results demonstrate that long‐term oral vancomycin exacerbates cholestatic liver injury, while C. scindens mitigates this effect by activating the intestinal FXR‐FGF15/19 signaling pathway. This underscores the importance of monitoring bile acid levels in PSC patients receiving vancomycin treatment and suggests that C. scindens may serve as a potential therapeutic approach for PSC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinFibroblast Growth FactorsLiver CirrhosisCholestasisReceptors, Cytoplasmic and NuclearClostridiumAnimalsMiceSignal TransductionAnti-Bacterial AgentsMaleBile Acids and SaltsMice, Inbred C57BLGastrointestinal MicrobiomeHumansReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

Clostridium scindensFXR‐FGF15/19 signalingcholestatic liver diseasesgut microbiotaliver fibrosisvancomycin

Substanzen

VancomycinFibroblast Growth FactorsReceptors, Cytoplasmic and NuclearAnti-Bacterial AgentsBile Acids and SaltsReceptor, Farnesoid X-Activatedfibroblast growth factor 15, mouse

Autor:innen und Institutionen

  • Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Department of Clinical Pharmacology, Xiangya Hospital, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan, 410008, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.

ORCID-Profile: Jintao Xiao, Xiaowei Liu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Xiao, J., Hou, Y., Luo, X., Zhu, Y., Li, W., Li, B., Zhou, L., Chen, X., Guo, Y., Zhang, X., He, H., & Liu, X. (2025). Clostridium Scindens Protects Against Vancomycin‐Induced Cholestasis and Liver Fibrosis by Activating Intestinal FXR‐FGF15/19 Signaling. Advanced Science, 12(5). https://doi.org/10.1002/advs.202406445

Vancouver

Xiao J, Hou Y, Luo X, Zhu Y, Li W, Li B, et al. Clostridium Scindens Protects Against Vancomycin‐Induced Cholestasis and Liver Fibrosis by Activating Intestinal FXR‐FGF15/19 Signaling. Advanced Science. 2025;12(5). doi:10.1002/advs.202406445

BibTeX
@article{Xiao2025,
  author = {Xiao, Jintao and Hou, Yanliang and Luo, Xingyang and Zhu, Yuhao and Li, Wenhu and Li, Bingbing and Zhou, LinXiang and Chen, Xia and Guo, Ying and Zhang, Xiaomei and He, Haiyue and Liu, Xiaowei},
  title = {Clostridium Scindens Protects Against Vancomycin‐Induced Cholestasis and Liver Fibrosis by Activating Intestinal FXR‐FGF15/19 Signaling},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {5},
  doi = {10.1002/advs.202406445}
}
Kostenlos starten →